Compare ADMA Biologics Inc (ADMA) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Church & Dwight Co., Inc. — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Church & Dwight Co., Inc. trades at $97.16 (market cap $23.45B). The key difference: Church & Dwight Co., Inc. is far larger — about 11× ADMA Biologics Inc's market cap, and Church & Dwight Co., Inc. pays a 1.41% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CHD | |
|---|---|---|
Market Cap | $2.13B | $23.45B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $105.26 |
52-Week Low | $7.60 | $81.60 |
Enterprise Value | $2.20B | $25.15B |
Dividend Yield | — | 1.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Church & Dwight (CHD) trades at $98.95, up 0.35% with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q1 2026 adjusted EPS of $0.95 beating the $0.93 estimate (Zacks Investment Research, 2026-05-01). Recent acquisition of Miss Mouth's brand for $325 million strengthens its fabric care portfolio. Valuation metrics show a P/E of 32.43 and ROE of 16.78%, indicating premium pricing but strong profitability.
Outlook remains positive with 53% analyst buy ratings and a $100.50 consensus target, though net cash flow turned negative in 2025. Risks include cost pressures impacting margins, as seen in Q1 profit slippage (WSJ, 2026-05-01), and high debt levels. The stock offers growth potential through organic sales expansion and strategic acquisitions, but investors should monitor margin sustainability and competitive dynamics in consumer staples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
